↓ Skip to main content

Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer–A multicenter randomized phase III…

Overview of attention for article published in BMC Cancer, May 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer–A multicenter randomized phase III clinical trial (SENORITA trial) protocol
Published in
BMC Cancer, May 2016
DOI 10.1186/s12885-016-2336-8
Pubmed ID
Authors

Ji Yeon Park, Young-Woo Kim, Keun Won Ryu, Byung-Ho Nam, Young Joon Lee, Sang Ho Jeong, Ji-Ho Park, Hoon Hur, Sang-Uk Han, Jae Seok Min, Ji Yeong An, Woo Jin Hyung, Gyu Seok Cho, Gui Ae Jeong, Oh Jeong, Young Kyu Park, Mi Ran Jung, Hong Man Yoon, Bang Wool Eom

Abstract

Along with the marked increase in early gastric cancer (EGC) in the Eastern countries, there has been an effort to adopt the sentinel node concept in EGC to preserve gastric function and reduce the occurrence of postoperative complications. Based on promising results from a previous quality control study, this prospective multicenter randomized controlled phase III clinical trial aims to elucidate the oncologic safety of laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD) compared to a standard laparoscopic gastrectomy. This trial is an investigator-initiated, open-label, multicenter randomized controlled phase III trial with a non-inferiority design. Patients diagnosed with a single lesion of clinical stage T1N0M0 gastric adenocarcinoma, with a diameter of 3 cm or less are eligible for the present study. A total of 580 patients (290 per group) will be randomized to either laparoscopic stomach-preserving surgery with SBD or standard surgery. The primary end-point is 3-year disease-free survival (DFS) and the secondary endpoints include postoperative morbidity and mortality, quality of life, 5-year DFS, and overall survival. Qualified investigators who completed the prior quality control study are exclusively allowed to participate in this phase III clinical trial. The proposed trial is expected to verify whether laparoscopic stomach-preserving surgery with SBD achieves similar oncologic outcomes and improved quality of life compared to a standard gastrectomy in EGC patients. This study was registered at the NIH ClinicalTrial.gov database ( NCT01804998 ) on March 4th, 2013.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Other 7 11%
Student > Bachelor 7 11%
Researcher 6 10%
Student > Ph. D. Student 4 7%
Student > Postgraduate 4 7%
Other 13 21%
Unknown 20 33%
Readers by discipline Count As %
Medicine and Dentistry 25 41%
Nursing and Health Professions 6 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Biochemistry, Genetics and Molecular Biology 2 3%
Business, Management and Accounting 1 2%
Other 5 8%
Unknown 20 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2016.
All research outputs
#21,264,673
of 23,881,329 outputs
Outputs from BMC Cancer
#6,689
of 8,483 outputs
Outputs of similar age
#298,540
of 342,361 outputs
Outputs of similar age from BMC Cancer
#125
of 157 outputs
Altmetric has tracked 23,881,329 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,483 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,361 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 157 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.